• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

为十二指肠溃疡和胃食管反流病的最佳愈合进行适当的抑酸治疗。

Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease.

作者信息

Howden C W, Burget D W, Hunt R H

机构信息

University of South Carolina School of Medicine, Columbia.

出版信息

Scand J Gastroenterol Suppl. 1994;201:79-82. doi: 10.3109/00365529409105369.

DOI:10.3109/00365529409105369
PMID:8047830
Abstract

Comparisons of the effectiveness of treatments for healing duodenal ulcer are essential to determine optimal management strategies for both economic analysis and quality-of-life evaluation. Differences are usually made on the basis of the proportion of ulcers healed at varying time intervals. It has been shown by meta-analysis that healing of duodenal ulcers with antisecretory drugs is directly correlated to the degree of acid suppression. More recently, sophisticated meta-analysis of 24-hour intragastric acidity data and clinical trials of antisecretory drugs has demonstrated that the optimal degree and duration of gastric acid suppression for healing duodenal ulcer can be achieved by an aggregate time above pH 3 of 18-20 hours/day. These conditions predict 100% ulcer healing at 4 weeks. Antisecretory drug regimens that approach these criteria should achieve faster healing than other agents, with a concomitant acceleration of symptom resolution. Regression analysis was performed on the healing-time curves for each drug class to determine the rate of ulcer healing per week. The mean proportion of ulcers healed, irrespective of treatment duration, was highest for omeprazole, which also provided a significantly faster rate of duodenal ulcer healing than all other drug classes (p < 0.001). It has recently been shown that healing of erosive oesophagitis with antisecretory drugs is directly correlated with both the duration of acid suppression over the 24-hour period (p < 0.05) and the elevation of intra-oesophageal pH above 4. Furthermore, oesophageal acid exposure time can be normalized by maintaining the intra-oesophageal pH above 4 for at least 96% of the 24-hour period.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

比较十二指肠溃疡治疗方法的有效性对于确定经济分析和生活质量评估的最佳管理策略至关重要。差异通常基于不同时间间隔愈合的溃疡比例。荟萃分析表明,使用抗分泌药物治疗十二指肠溃疡与胃酸抑制程度直接相关。最近,对24小时胃内酸度数据的精密荟萃分析以及抗分泌药物的临床试验表明,通过使pH值高于3的总时间达到每天18 - 20小时,可实现十二指肠溃疡愈合所需的胃酸抑制的最佳程度和持续时间。这些条件预计在4周时溃疡愈合率为100%。接近这些标准的抗分泌药物治疗方案应比其他药物实现更快的愈合,并伴随症状缓解加速。对每种药物类别的愈合时间曲线进行回归分析,以确定每周溃疡愈合率。无论治疗持续时间如何,奥美拉唑愈合的溃疡平均比例最高,其十二指肠溃疡愈合速度也明显快于所有其他药物类别(p < 0.001)。最近有研究表明,使用抗分泌药物治疗糜烂性食管炎与24小时内胃酸抑制持续时间(p < 0.05)以及食管内pH值高于4均直接相关。此外,通过在24小时内至少96%的时间将食管内pH值维持在4以上,可使食管酸暴露时间正常化。(摘要截选于250字)

相似文献

1
Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease.为十二指肠溃疡和胃食管反流病的最佳愈合进行适当的抑酸治疗。
Scand J Gastroenterol Suppl. 1994;201:79-82. doi: 10.3109/00365529409105369.
2
Optimizing acid suppression for treatment of acid-related diseases.优化抑酸治疗酸相关性疾病
Dig Dis Sci. 1995 Feb;40(2 Suppl):24S-49S. doi: 10.1007/BF02214870.
3
Appropriate acid suppression in the treatment of acid-related conditions.
Pharmacol Ther. 1994;63(1):123-34. doi: 10.1016/0163-7258(94)90056-6.
4
Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs.十二指肠溃疡的抑酸治疗:一项旨在确定抗分泌药物最佳剂量的荟萃分析。
Gut. 1987 Sep;28(9):1120-7. doi: 10.1136/gut.28.9.1120.
5
Ranitidine in the treatment of duodenal ulcer disease: relationship between antisecretory effect and ulcer healing rate.雷尼替丁治疗十二指肠溃疡病:抗分泌作用与溃疡愈合率之间的关系。
Aliment Pharmacol Ther. 1991 Jun;5(3):227-43. doi: 10.1111/j.1365-2036.1991.tb00024.x.
6
Idiopathic gastric acid hypersecretion: treatment implications for refractory acid/peptic disorders.特发性胃酸分泌过多:对难治性酸/消化性疾病的治疗意义
Aliment Pharmacol Ther. 1991;5 Suppl 1:15-24. doi: 10.1111/j.1365-2036.1991.tb00745.x.
7
pH, healing rate and symptom relief in acid-related diseases.酸相关性疾病中的pH值、愈合率及症状缓解情况
Yale J Biol Med. 1996 Mar-Apr;69(2):159-74.
8
Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression.十二指肠溃疡愈合是否存在最佳抑酸程度?溃疡愈合与抑酸之间关系的模型。
Gastroenterology. 1990 Aug;99(2):345-51. doi: 10.1016/0016-5085(90)91015-x.
9
Rabeprazole: a review of its use in acid-related gastrointestinal disorders.雷贝拉唑:其在酸相关性胃肠疾病中的应用综述
Drugs. 1999 Oct;58(4):725-42. doi: 10.2165/00003495-199958040-00014.
10
Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders.综述文章:雷贝拉唑治疗酸相关性疾病的pH值、愈合情况及症状缓解
Aliment Pharmacol Ther. 2004 Nov;20 Suppl 6:30-7. doi: 10.1111/j.1365-2036.2004.02163.x.

引用本文的文献

1
Efficacy and safety of vonoprazan versus proton pump inhibitors in the treatment of peptic ulcer disease: a systematic review and network meta-analysis for randomized controlled trails.沃克(沃克)与质子泵抑制剂治疗消化性溃疡疾病的疗效和安全性:一项随机对照试验的系统评价和网状荟萃分析
Front Nutr. 2024 Sep 5;11:1436993. doi: 10.3389/fnut.2024.1436993. eCollection 2024.
2
Comparative Efficacy and Safety of Potassium-Competitive Acid Blockers vs. Proton Pump Inhibitors for Peptic Ulcer with or without Infection: A Systematic Review and Network Meta-Analysis.钾离子竞争性酸阻滞剂与质子泵抑制剂治疗伴或不伴感染的消化性溃疡的疗效和安全性比较:一项系统评价和网状Meta分析
Pharmaceuticals (Basel). 2024 May 28;17(6):698. doi: 10.3390/ph17060698.
3
Comparative efficiency and safety of potassium competitive acid blockers Lansoprazole in peptic ulcer: a systematic review and meta-analysis.钾离子竞争性酸阻滞剂与兰索拉唑治疗消化性溃疡的比较疗效及安全性:一项系统评价和Meta分析
Front Pharmacol. 2024 Jan 11;14:1304552. doi: 10.3389/fphar.2023.1304552. eCollection 2023.
4
Efficacy and Safety of Keverprazan Compared With Lansoprazole in the Treatment of Duodenal Ulcer: A Phase III, Randomized, Double-Blind, Multicenter Trial.可韦拉唑与兰索拉唑治疗十二指肠溃疡的疗效和安全性:一项 III 期、随机、双盲、多中心试验。
Clin Transl Gastroenterol. 2023 Jul 1;14(7):e00602. doi: 10.14309/ctg.0000000000000602.
5
Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency.基于相对效力的质子泵抑制剂的可互换使用。
Clin Gastroenterol Hepatol. 2018 Jun;16(6):800-808.e7. doi: 10.1016/j.cgh.2017.09.033. Epub 2017 Sep 28.
6
Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options.酪氨酸激酶抑制剂与质子泵抑制剂:治疗方案评估
Clin Pharmacokinet. 2017 Jul;56(7):683-688. doi: 10.1007/s40262-016-0503-3.
7
Acid peptic diseases: pharmacological approach to treatment.酸相关性疾病:治疗的药理学方法
Expert Rev Clin Pharmacol. 2009 May;2(3):295-314. doi: 10.1586/ecp.09.8.
8
Comparing resource utilization and gastrointestinal outcomes in patients treated with either standard-dose or high-dose proton pump inhibitors: a matched cohort study.比较接受标准剂量或高剂量质子泵抑制剂治疗的患者的资源利用情况和胃肠道结局:一项匹配队列研究。
Dig Dis Sci. 2008 Jun;53(6):1519-26. doi: 10.1007/s10620-007-0031-y.
9
Esomeprazole 20mg provides more effective intragastric Acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers.埃索美拉唑 20mg 在健康志愿者中比维持剂量雷贝拉唑、兰索拉唑或泮托拉唑提供更有效的胃酸控制。
Clin Drug Investig. 2004;24(1):1-7. doi: 10.2165/00044011-200424010-00001.
10
Diagnostic interpretation of extended pH monitoring: is there a single best method?延长pH监测的诊断解读:是否存在单一的最佳方法?
Dig Dis Sci. 2005 Jan;50(1):94-9. doi: 10.1007/s10620-005-1284-y.